Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GR1405 in advanced solid tumors or lymphoma
NCT03731390Phase 1Unknown
- Sponsor
- Chinese Academy of Medical Sciences
- Start
- Nov 2018
- Primary completion
- Oct 2019
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of GR-1405 in solid tumor and lymphoma (4 arms), sponsored by Chinese Academy of Medical Sciences. Primary endpoints: Maximum Tolerated Dose at 2 weeks and Adverse Events at 3 years. Status: unknown.
02
Drugs
GR-1405
03
Conditions
solid tumorlymphoma
Beyond the preview
Go deeper on NCT03731390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03731390.